OIS at AAO 2015

Envisia Therapeutics

Nov 12, 2015 8:46am ‐ Nov 12, 2015 8:54am


Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma.


You must be logged in and own this session in order to post comments.